Biography
Daniel leads the biopharma and data partnerships efforts at Invitae where he is responsible for building the network of partners to improve the quality of healthcare for patients. Prior to joining Invitae, he worked in J.P. Morgan’s healthcare investment banking group where he advised biotech and medtech companies on M&A, capital raising and other strategic transactions. Daniel started his career at the management consulting firm ZS Associates where he specialized in addressing healthcare sales and marketing issues. He also worked in South Africa and Tanzania to expand access to vaccination programs. Daniel lives in Denver, Colorado with his wife, daughter and son.
Track Chair:
Ed Esplin, Invitae
Genetic testing has evolved over time and various applications have successfully made it into the clinical setting. While oncology applications are dominating, we also see a rise in genetic/genomic applications for reproductive health, CVD diagnosis, or early life understanding. Technological advancements are required to scale genetic testing applications delivery including relay of genomic information to clinicians and patients. In parallel to technological challenges, hurdles are also observed when it comes to insight/knowledge extraction, reporting of clinical findings, and scaling of genetic counseling. This track will touch upon these various aspects including successful precision medicine models through biopharma ventures for rare disease understanding and direct to consumer genetic testing.
Sessions: